Published in PLoS Med on November 15, 2005
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest (2011) 2.58
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci (2011) 1.79
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron (2014) 1.67
Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging (2010) 1.45
Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem (2007) 1.27
Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev (2009) 1.24
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct (2009) 1.20
Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci (2014) 1.11
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener (2009) 1.07
Validation of a rodent model of episodic memory. Anim Cogn (2010) 1.03
Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. Brain (2016) 1.01
Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci (2012) 1.01
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci (2014) 1.00
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther (2009) 1.00
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration. Cell Rep (2015) 0.96
Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid Redox Signal (2010) 0.96
Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS One (2013) 0.96
Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci (2013) 0.95
Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer's disease. Neuroimage (2009) 0.95
Quantitative mouse brain phenotyping based on single and multispectral MR protocols. Neuroimage (2012) 0.94
Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener (2012) 0.94
Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am J Pathol (2008) 0.92
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev (2012) 0.89
Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. Exp Neurol (2009) 0.89
Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment. Hum Mol Genet (2011) 0.89
Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci (2009) 0.89
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther (2013) 0.88
Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des (2012) 0.88
In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function. J Neurosci (2011) 0.88
Receptor-associated protein (RAP) plays a central role in modulating Abeta deposition in APP/PS1 transgenic mice. PLoS One (2008) 0.87
Ageing increases vulnerability to aβ42 toxicity in Drosophila. PLoS One (2012) 0.87
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Snapin-mediated BACE1 retrograde transport is essential for its degradation in lysosomes and regulation of APP processing in neurons. Cell Rep (2013) 0.86
An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum Mol Genet (2015) 0.86
The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol (2010) 0.86
Cerebral vascular leak in a mouse model of amyloid neuropathology. J Cereb Blood Flow Metab (2014) 0.85
Prospective cognition in rats. Learn Motiv (2012) 0.85
Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem (2012) 0.85
A preclinical assessment of neural stem cells as delivery vehicles for anti-amyloid therapeutics. PLoS One (2012) 0.84
Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol (2008) 0.84
Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet (2015) 0.84
Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model. J Neurosci (2013) 0.83
HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships. Future Virol (2012) 0.83
Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct Funct (2015) 0.82
Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci (2016) 0.82
Wild-type neural progenitors divide and differentiate normally in an amyloid-rich environment. J Neurosci (2013) 0.81
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. Nat Commun (2016) 0.81
The entorhinal cortex and neurotrophin signaling in Alzheimer's disease and other disorders. Cogn Neurosci (2013) 0.81
Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models. Brain Behav Immun (2016) 0.80
A prior feature SVM-MRF based method for mouse brain segmentation. Neuroimage (2011) 0.80
Emerging Link between Alzheimer's Disease and Homeostatic Synaptic Plasticity. Neural Plast (2016) 0.80
Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. Curr Alzheimer Res (2015) 0.79
Apomorphine and Alzheimer Aβ: roles for regulated α cleavage, autophagy, and antioxidation? Ann Neurol (2011) 0.78
Optogenetic measurement of presynaptic calcium transients using conditional genetically encoded calcium indicator expression in dopaminergic neurons. PLoS One (2014) 0.78
Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease. J Neurosci (2017) 0.77
Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. J Alzheimers Dis (2015) 0.77
Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits. Acta Neuropathol Commun (2015) 0.77
Loss of presenilin function is associated with a selective gain of APP function. Elife (2016) 0.77
Breaking up (amyloid) is hard to do. PLoS Med (2005) 0.77
Impaired Recall of Positional Memory following Chemogenetic Disruption of Place Field Stability. Cell Rep (2016) 0.77
Laminar specific detection of APP induced neurodegeneration and recovery using MEMRI in an olfactory based Alzheimer's disease mouse model. Neuroimage (2015) 0.76
Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem (2014) 0.76
Impaired retrograde transport of axonal autophagosomes contributes to autophagic stress in Alzheimer's disease neurons. Elife (2017) 0.75
Detection of Aβ plaque deposition in MR images based on pixel feature selection and class information in image level. Biomed Eng Online (2016) 0.75
APP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway. eNeuro (2016) 0.75
Cellular Regulation of Amyloid Formation in Aging and Disease. Front Neurosci (2017) 0.75
Generation of a new transgenic mouse model for assessment of tau gene silencing therapies. Alzheimers Res Ther (2016) 0.75
Imaging biophysics of axonal transport with MEMRI: Optic tract transport is altered in mouse model of Alzheimer's disease. Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib (2009) 0.75
A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. J Alzheimers Dis (2016) 0.75
Amyloid-β plaques disrupt axon initial segments. Exp Neurol (2016) 0.75
Magnetic resonance microscopy. Anal Cell Pathol (Amst) (2012) 0.75
Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction. PLoS One (2016) 0.75
Impairments in experience-dependent scaling and stability of hippocampal place fields limit spatial learning in a mouse model of Alzheimer's disease. Hippocampus (2014) 0.75
Seizure-Induced Regulations of Amyloid-β, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity. Neural Plast (2016) 0.75
Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. J Neurosci (2017) 0.75
A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism. Alzheimers Res Ther (2017) 0.75
Genomic sequencing. Proc Natl Acad Sci U S A (1984) 92.36
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Control of memory formation through regulated expression of a CaMKII transgene. Science (1996) 7.56
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 6.45
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A (1996) 5.93
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A (1994) 5.71
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell (1989) 4.99
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A (1998) 4.14
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A (1994) 3.36
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal (1996) 3.18
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol (1986) 3.09
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem (2003) 2.31
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis (2005) 2.22
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet (2002) 1.96
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging (2001) 1.79
Prion clearance in bigenic mice. J Gen Virol (2005) 1.79
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci (1993) 1.54
Nerve inflammation halts trial for Alzheimer's drug. Nature (2002) 1.44
Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. Trends Pharmacol Sci (2004) 1.41
Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther (2004) 1.32
The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging (2001) 1.31
Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci (1999) 1.25
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol (2004) 1.18
Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov (2002) 1.09
Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch (2002) 0.99
Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. Alzheimer Dis Assoc Disord (2002) 0.94
Genetics of early-onset Alzheimer dementia. ScientificWorldJournal (2003) 0.93
Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Brain Res (2004) 0.88
Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Devel (2004) 0.87
The search for gamma-secretase and development of inhibitors. Curr Med Chem (2002) 0.84
Ca2+/calmodulin protein kinase and protein kinase C expression during development of rat hippocampus. Dev Neurosci (1993) 0.79
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res (2003) 12.94
Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res (2005) 11.23
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science (2004) 5.94
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Identification of Vangl2 and Scrb1 as planar polarity genes in mammals. Nature (2003) 4.56
RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res (2004) 4.41
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
New genes involved in cancer identified by retroviral tagging. Nat Genet (2002) 4.14
Identification of an organelle receptor for myosin-Va. Nat Cell Biol (2002) 4.06
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse. Proc Natl Acad Sci U S A (2003) 3.93
Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet (2004) 3.78
The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol (2008) 3.55
Bcl11a is essential for normal lymphoid development. Nat Immunol (2003) 3.48
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci (2005) 3.23
Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature (2005) 3.18
Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood (2005) 2.93
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 2.90
A proposal for a coordinated effort for the determination of brainwide neuroanatomical connectivity in model organisms at a mesoscopic scale. PLoS Comput Biol (2009) 2.88
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85
Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet (2003) 2.78
Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science (2010) 2.77
Asymmetric localization of Vangl2 and Fz3 indicate novel mechanisms for planar cell polarity in mammals. J Neurosci (2006) 2.73
Region-specific saturation germline mutagenesis in mice using the Sleeping Beauty transposon system. Nat Methods (2005) 2.70
In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron (2008) 2.69
Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum Mol Genet (2003) 2.64
RGS9 modulates dopamine signaling in the basal ganglia. Neuron (2003) 2.61
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J (2004) 2.55
Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet (2002) 2.46
The structural basis of function in Cys-loop receptors. Q Rev Biophys (2010) 2.45
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain (2009) 2.45
Harnessing transposons for cancer gene discovery. Nat Rev Cancer (2010) 2.44
Myosin-1a is critical for normal brush border structure and composition. Mol Biol Cell (2005) 2.44
Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci (2007) 2.37
Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23
Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry (2002) 2.22
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis (2005) 2.22
Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature (2009) 2.21
Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol (2003) 2.20
Efficient Cre-loxP-induced mitotic recombination in mouse embryonic stem cells. Nat Genet (2001) 2.14
Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis (2002) 2.14
High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation. Neurobiol Dis (2002) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05